Tag: 9999

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

As previously announced on July 8, 2025, the upcoming reverse share split could not be carried out due to unforeseen technical issues beyond Fingerprint Cards AB’s (publ) (“FPC” or the “Company”) control and the Company withdrew the resolution for the record date planned to be held on July 11, 2025.

At the Annual General Meeting of Fingerprint Cards AB (publ) (“FPC” or the “Company”) held on June 24, 2025, a resolution was passed to carry out a reverse share split, whereby two thousand (2,000) existing shares will be consolidated into one (1) new share (reverse split 1:2,000). The AGM also resolved to authorize the Board of Directors to determine the record date for the reverse split.

Gothenburg, Sweden – June 26, 2025 – Fingerprint Cards AB (FPC) is pleased to announce the appointment of two distinguished new members to its Board of Directors following the company’s Annual General Meeting held on 24^th June, 2025. The shareholders voted in favour of appointing John Lord and Carl Johan Grandinson to the board, marking a pivotal step in FPC’s evolution as it enters an exciting new chapter of innovation and strategic transformation.

Gothenburg, Sweden and Oslo, Norway – June 24, 2025 – Fingerprint Cards AB (FPC), a global leader in biometric authentication technologies, is excited to announce that its partner, Fuse Identities, has launched its latest product, a cutting-edge biometric physical access card, equipped with the advanced FPC 1323 T-Shape sensor. This breakthrough solution delivers a new standard of secure, contactless identity verification for modern access control systems.